Microbiome-derived TOPOSCORE is associated with response to immune checkpoint inhibitor re-induction after chemotherapy in primary resistant metastatic melanoma.

What was studied

This study looked at gut germs in people with melanoma that had spread. Their cancer had not responded to immune drugs. In the PROMIT trial, they got chemotherapy first. Then they got the immune drug again. The analysis used 24 people with stool samples. It asked if gut germ patterns, called TOPOSCORE, were linked to response.

What they found

Baseline TOPOSCORE was not linked to outcome. Among people with full sampling, most kept the same category. A few changed category. Of the people with a partial response, 1 stayed in SIG2. The other changed and then changed back. Scores did not differ between response groups.

What it means for patients

The authors say baseline TOPOSCORE could not predict the outcome here. They say patterns over time varied. They say these early findings support more study in larger groups.

Why it is not certain yet

Few people had full sampling. The authors say this prevents firm conclusions. They cannot say chemotherapy caused a helpful change in the gut. The analysis was exploratory. The abstract names no comparison group.

Source

Microbiome-derived TOPOSCORE is associated with response to immune checkpoint inhibitor re-induction after chemotherapy in primary resistant metastatic melanoma.

We restate facts from the source record in our own words. The original wording belongs to its publisher.